C-Reactive Protein, High-Molecular-Weight Adiponectin and Development of Metabolic Syndrome in the Japanese General Population: A Longitudinal Cohort Study

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Saisho, Yoshifumi ^a   Hirose, Hiroshi ^a   Roberts, Rachel ^a   Abe, Takayuki ^a   Kawabe, Hiroshi ^a   Itoh, Hiroshi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN;

ADULT; ARTICLE; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HUMAN; JAPANESE; LONGITUDINAL STUDY; MALE; METABOLIC SYNDROME X; MOLECULAR WEIGHT; PREDICTIVE VALUE; WAIST CIRCUMFERENCE; ASIAN; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PROSPECTIVE STUDY; ASIAN CONTINENTAL ANCESTRY GROUP;

ADIPONECTIN; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BODY MASS INDEX; C-REACTIVE PROTEIN; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROSPECTIVE STUDIES; WAIST CIRCUMFERENCE;

EID: 84884198622     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073430     Document Type: Article

References (36)

1. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, et al. (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120: 1640-1645.
2. Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D, (2012) Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care 35: 2402-2411.
3. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB, (1999) Elevated C-reactive protein levels in overweight and obese adults. JAMA 282: 2131-2135.
4. Ford ES, (2003) The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third National Health and Nutrition Examination Survey. Atherosclerosis 168: 351-358.
5. Yatagai T, Nagasaka S, Taniguchi A, Fukushima M, Nakamura T, et al. (2003) Hypoadiponectinemia is associated with visceral fat accumulation and insulin resistance in Japanese men with type 2 diabetes mellitus. Metabolism 52: 1274-1278.
6. Matsushita K, Yatsuya H, Tamakoshi K, Wada K, Otsuka R, et al. (2006) Comparison of circulating adiponectin and proinflammatory markers regarding their association with metabolic syndrome in Japanese men. Arterioscler Thromb Vasc Biol 26: 871-876.
7. Corrado E, Rizzo M, Coppola G, Fattouch K, Novo G, et al. (2010) An update on the role of markers of inflammation in atherosclerosis. J Atheroscler Thromb 17: 1-11.
8. Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, et al. (2002) Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360: 57-58.
9. Daimon M, Oizumi T, Saitoh T, Kameda W, Hirata A, et al. (2003) Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese Population: the Funagata study. Diabetes Care 26: 2015-2020.
10. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, et al. (2004) Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291: 1730-1737.
11. Inoue T, Kotooka N, Morooka T, Komoda H, Uchida T, et al. (2007) High molecular weight adiponectin as a predictor of long-term clinical outcome in patients with coronary artery disease. Am J Cardiol 100: 569-574.
12. Ministry of Health, Labor and Welfare (Japan) (2007) National Health and Nutrition Survey.
13. Saisho Y, Hirose H, Seino Y, Saito I, Itoh H, (2010) Usefulness of C-Reactive Protein to High-Molecular-Weight Adiponectin Ratio to Predict Insulin Resistance and Metabolic Syndrome in Japanese Men. J Atheroscler Thromb 17: 944-952.
14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419.
15. Nakano Y, Tajima S, Yoshimi A, Akiyama H, Tsushima M, et al. (2006) A novel enzyme-linked immunosorbent assay specific for high-molecular-weight adiponectin. J Lipid Res 47: 1572-1582.
16. Seino Y, Hirose H, Saito I, Itoh H, (2007) High molecular weight multimer form of adiponectin as a useful marker to evaluate insulin resistance and metabolic syndrome in Japanese men. Metabolism 56: 1493-1499.
17. Seino Y, Hirose H, Saito I, Itoh H, (2009) High-molecular-weight adiponectin is a predictor of progression to metabolic syndrome: a population-based 6-year follow-up study in Japanese men. Metabolism 58: 355-360.
18. Hirose H, Yamamoto Y, Seino-Yoshihara Y, Kawabe H, Saito I, (2010) Serum high-molecular-weight adiponectin as a marker for the evaluation and care of subjects with metabolic syndrome and related disorders. J Atheroscler Thromb 17: 1201-1211.
19. Alberti KG, Zimmet P, Shaw J, (2006) Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 23: 469-480.
20. The Examination Committee for Criteria of Metabolic Syndrome (2005) Definition and criteria of metabolic syndrome. J Jpn Soc Intern Med 94: 794-809 (in Japanese).
21. Kahn SE, Zinman B, Haffner SM, O'Neill MC, Kravitz BG, et al. (2006) Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes. Diabetes 55: 2357-2364.
22. Timpson NJ, Lawlor DA, Harbord RM, Gaunt TR, Day IN, et al. (2005) C-reactive protein and its role in metabolic syndrome: mendelian randomisation study. Lancet 366: 1954-1959.
23. Aronson D, Bartha P, Zinder O, Kerner A, Markiewicz W, et al. (2004) Obesity is the major determinant of elevated C-reactive protein in subjects with the metabolic syndrome. Int J Obes Relat Metab Disord 28: 674-679.
24. Yamauchi T, Kamon J, Waki H, Imai Y, Shimozawa N, et al. (2003) Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 278: 2461-2468.
25. Hara K, Horikoshi M, Yamauchi T, Yago H, Miyazaki O, et al. (2006) Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 29: 1357-1362.
26. Aso Y, Yamamoto R, Wakabayashi S, Uchida T, Takayanagi K, et al. (2006) Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin. Diabetes 55: 1954-1960.
27. Basu R, Pajvani UB, Rizza RA, Scherer PE, (2007) Selective downregulation of the high molecular weight form of adiponectin in hyperinsulinemia and in type 2 diabetes: differential regulation from nondiabetic subjects. Diabetes 56: 2174-2177.
28. Tabara Y, Osawa H, Kawamoto R, Tachibana-Iimori R, Yamamoto M, et al. (2008) Reduced high-molecular-weight adiponectin and elevated high-sensitivity C-reactive protein are synergistic risk factors for metabolic syndrome in a large-scale middle-aged to elderly population: the Shimanami Health Promoting Program Study. J Clin Endocrinol Metab 93: 715-722.
29. Devaraj S, Swarbrick MM, Singh U, Adams-Huet B, Havel PJ, et al. (2008) CRP and adiponectin and its oligomers in the metabolic syndrome: evaluation of new laboratory-based biomarkers. Am J Clin Pathol 129: 815-822.
30. Ong KL, Tso AW, Xu A, Law LS, Li M, et al. (2011) Evaluation of the combined use of adiponectin and C-reactive protein levels as biomarkers for predicting the deterioration in glycaemia after a median of 5.4 years. Diabetologia 54: 2552-2560.
31. Chao C, Song Y, Cook N, Tseng CH, Manson JE, et al. (2010) The lack of utility of circulating biomarkers of inflammation and endothelial dysfunction for type 2 diabetes risk prediction among postmenopausal women: the Women's Health Initiative Observational Study. Arch Intern Med 170: 1557-1565.
32. Dallmeier D, Larson MG, Wang N, Fontes JD, Benjamin EJ, et al. (2012) Addition of inflammatory biomarkers did not improve diabetes prediction in the community: the framingham heart study. J Am Heart Assoc 1: e000869.
33. Wannamethee SG, Whincup PH, Lennon L, Sattar N, (2007) Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. Arch Intern Med 167: 1510-1517.
34. Kizer JR, Benkeser D, Arnold AM, Mukamal KJ, Ix JH, et al. (2012) Associations of total and high-molecular-weight adiponectin with all-cause and cardiovascular mortality in older persons: the Cardiovascular Health Study. Circulation 126: 2951-2961.
35. Kizer JR, Benkeser D, Arnold AM, Djousse L, Zieman SJ, et al. (2013) Total and high-molecular-weight adiponectin and risk of coronary heart disease and ischemic stroke in older adults. J Clin Endocrinol Metab 98: 255-263.
36. Saito I, Yamagishi K, Chei CL, Cui R, Ohira T, et al. (2013) Total and high molecular weight adiponectin levels and risk of cardiovascular disease in individuals with high blood glucose levels. Atherosclerosis Epub ahead of print.